Milwaukee, WI Clinical Trials Report — July 2026

Milwaukee participants should act quickly on studies nearing enrollment deadlines: 30 recruiting trials are expected to close within the next 90 days, including 7 that accept healthy volunteers. Milwaukee has 632 recruiting trials across 180 research facilities, so people who find a potentially suitable study should contact the research site soon rather than wait for the projected closing date.

July also brought 8 new trial openings, up from 4 in May. None of the new studies accept healthy volunteers, but Milwaukee has 47 healthy-volunteer trials recruiting overall. The July openings are concentrated in cancer, cystic fibrosis, and prolonged grief disorder, with most classified as drug studies.

Closing windows in cancer, aging, and pediatric conditions

The trials closing soon cover a wide range of conditions. The largest listed category is hematologic testing, while several studies involve blood cancers and other serious diseases. The conditions represented among closing-soon trials include:

• Hematologic tests (2 trials)
• Advanced solid tumor (1 trial)
• B-cell acute lymphoblastic leukemia (1 trial)
• Acute myeloid leukemia, or AML (1 trial)
• AML with mutated NPM1 (1 trial)
• Athletic injuries (1 trial)
• Aging (1 trial)
• Cerebral palsy (1 trial)
• Congenital diaphragmatic hernia (1 trial)
• De novo prostate cancer (1 trial)

Seven closing-soon studies accept healthy volunteers, but the data does not identify how many open places remain in each study. Healthy-volunteer eligibility can depend on age, medication use, medical history, laboratory results, and willingness to complete study visits. People without a diagnosed condition should search the broader pool of 47 recruiting Milwaukee studies now, while patients with one of the listed conditions should ask study teams whether enrollment is still open.

AstraZeneca leads July’s late-stage openings

July’s new trials include 6 drug studies, 3 categorized as other, 2 biological studies, and 1 behavioral study. AstraZeneca accounts for 3 new studies, while the Medical College of Wisconsin sponsors 2. Five new studies are industry-sponsored and three are classified as other.

• NCT07720284 is an AstraZeneca Phase 3 study enrolling 915 adults with high-risk muscle-invasive urothelial carcinoma. It compares dato-DXd plus rilvegostomig with standard care after radical surgery for participants with high-risk residual disease.
• NCT07735637, also sponsored by AstraZeneca, is the Phase 3 DURGA-6 study for 750 transplant-eligible people with newly diagnosed multiple myeloma. It compares consolidation treatment with AZD0120 against autologous stem-cell transplantation, measuring progression-free survival and minimal residual disease outcomes.
• NCT07702578 is a Phase 3 study from TScan Therapeutics involving 310 participants undergoing allogeneic peripheral blood stem-cell transplantation. It evaluates genetically engineered donor T cells targeting HA-2 after reduced-intensity conditioning.
• NCT07690891 is a Medical College of Wisconsin Phase 2 study of nemtabrutinib with venetoclax and obinutuzumab for previously untreated chronic lymphocytic leukemia. The single-arm study plans to enroll 30 participants.
• NCT07696338, sponsored by Nicole Hamblett, is the REACT study of early airway-clearance therapies for people with cystic fibrosis. It includes parallel randomized studies of hypertonic saline and dornase alfa and plans to enroll 405 participants.

Other new July categories include B-cell non-Hodgkin lymphoma, AML, myelodysplastic syndromes, relapsed or refractory multiple myeloma, and prolonged grief disorder. Together, these openings give Milwaukee patients options across hematologic cancers, solid tumors, inherited lung disease, and behavioral health.

Medical College of Wisconsin is Milwaukee’s main research hub

The Medical College of Wisconsin is running far more recruiting studies than any other listed Milwaukee facility, with 228 trials. Its portfolio includes oncology, blood disorders, transplantation, cystic fibrosis, and other specialties. Aurora and Froedtert locations provide additional access across the city, while Children’s Hospital of Wisconsin and Children’s Wisconsin support pediatric research.

• Medical College of Wisconsin (228 trials)
• Aurora Sinai Medical Center (51 trials)
• Aurora Saint Luke’s Medical Center (48 trials)
• Aurora Cancer Care-Milwaukee (47 trials)
• Children’s Hospital of Wisconsin (45 trials)
• Research Site (22 trials)
• Froedtert Hospital and the Medical College of Wisconsin (19 trials)
• Froedtert Hospital & the Medical College of Wisconsin (17 trials)
• Children’s Wisconsin (16 trials)
• Froedtert Hospital (14 trials)

Several similarly named Froedtert and Medical College of Wisconsin listings appear separately in the data, so prospective participants should confirm the exact location and research team when making contact. Aurora Cancer Care-Milwaukee and the Medical College of Wisconsin are especially practical starting points for adults seeking oncology studies. Families looking for pediatric opportunities should check Children’s Hospital of Wisconsin and Children’s Wisconsin.

Eligibility and options outside Milwaukee

Among the 8 new July studies, 1 includes children and 7 include older adults. No new study is restricted to women or men, and none accepts healthy volunteers. These figures describe the new openings only; they do not limit the broader set of recruiting trials in Milwaukee.

People willing to travel can also search nearby Wisconsin communities. Madison has 11 recruiting trials, River Falls has 2, and Wauwatosa has 1. Madison therefore offers the largest nearby alternative in the supplied data, particularly for people whose condition or eligibility is not represented at a Milwaukee site.

Monthly new-trial activity has fluctuated: Milwaukee opened 7 trials in February, 10 in March, 3 in April, 6 in May, 4 in June, and 8 in July; the supplied trend also lists 2 for August. As summer enrollment continues, patients with blood cancers, urothelial cancer, multiple myeloma, cystic fibrosis, or other listed conditions should review eligibility and contact local sites before closing dates pass.